Age-specific prostate-specific antigen: A reassessment

Prostate

Volumn 29, Issue SUPPL. 7, 1996, Pages 70-77

  Etzioni, Ruth ^a   Shen, Yu ^c   Petteway, Jason C ^b   Brawer, Michael K ^b,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

age specific; PPV; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL TIME; AGING; ARTICLE; BIOPSY; LIFE EXPECTANCY; MASS SCREENING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; AGING; BIOPSY; HUMANS; LIFE EXPECTANCY; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030333435     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1996)7+<70::AID-PROS10>3.0.CO;2-O     Document Type: Conference Paper

References (29)

1. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP: Defining and updating the ACS guidelines for the cancer related check-up: Prostate and endometrial cancer. CA 43:42-46, 1993.
2. American Urological Association Executive Committee Report 4976. American Urological Association Annual Meeting, 1992.
3. Bazinet M, Meshref AW, Trudel C, Aronson S, Peloguin F, Nachabe M, Begin LR, Elhilali MM: Prospective evaluation of prostate specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 43:44-51, 1994.
4. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH: The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 147:817-821, 1992.
5. Rommel FM, Augusta VE, Breslin JA, Huffnagle HW, Pohl CE, Sieber PR, Stahl CA: The use of PSA and PSAD in the diagnosis of prostate cancer in a community based urology practice. J Urol 151:88-93, 1994.
6. Brawer MK, Aramburu EAG, Chen GL, Preston SD, Ellis WJ: The inability of PSA index to enhance the predictive value of PSA in the diagnosis of prostatic carcinoma. J Urol 150:369-373, 1993.
7. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, Mostofi FK: Relative sensitivity and specificity of serum PSA level compared with age-referenced PSA, PSA density and PSA change. Cancer 74:1615-1620, 1994.
8. Carter H, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, Chan DW, Fozard JL, Walsh PC: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52:3323-3328, 1992.
9. Pearson JD, Carter HB: Natural history of changes in PSA in early stage prostate cancer. J Urol 152:1743-1748, 1994.
10. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through PSA-based screening. JAMA 270:948-954, 1993.
11. Porter JR, Hayward R, Brawer MK: The significance of short-term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 151:293, 1994.
12. Brawer MK, Rennels MA, Nagle RB, Schifman RA, Gaines J: Serum PSA and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 92:760-764, 1989.
13. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
14. Ercole CJ, Lange PH, Mathisen M, Chiou RV, Reddy PK, Vessela RL: Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 138:1181-1184, 1987.
15. Ferro MA, Barnes I, Roberts JBM, Smith PJB: Tumor markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Br J Urol 60:69-73, 1987.
16. Hudson MA, Bahnson RB, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011-1017, 1989.
17. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum PSA in a community-based population of healthy men. JAMA 270: 860-864, 1993.
18. Dalkin BL, Ahmann FR, Kopp JB: PSA levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150:1837-1839, 1993.
19. Pauker SG, Kassirer JP: Decision analysis. N Engl J Med 916:250-258, 1987.
20. Tanner MA: Methods for the exploration of posterior distributions and likelihood functions. In (eds): "Springer Series in Statistics." Springer-Verlag, 1993, pp.
21. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH: Screening for prostatic carcinoma with PSA. J Urol 147:841-845, 1992.
22. Brawer MK, Beattie J, Wener MH, Vessella RL, Preston SD, Lange PH: Screening for prostatic carcinoma with PSA: Results of the second year. J Urol 150:106-109, 1993.
23. Brawer MK, Beatie J, Wener MH: PSA as the initial test in prostate carcinoma screening: Results of the third year. J Urol 149:299, 1993.
24. Ellis WJ, Chetner M, Preston S, Brawer MK: Diagnosis of prostatic carcinoma: The yield of serum PSA, DRE and TRUS. J Urol 152:1520-1525, 1994.
25. Catalona WJ, Smith DS, Ratcliff TL, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991.
26. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, de Kernion JB, Ratlife TL, Kavoussi LR, Dalkin BL, Waters WB, Macfarlane MT, Southwick PC: Comparison of DRE and serum PSA in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151:1283-1290, 1994.
27. Miller BA, Ries LAG, Hankey BF, Kosary CL, Harras A, Devesa SS, Edwards BK: "SEER Cancer Statistics Review: 1973-1990, National Cancer Institute." NIH Pub no. 93-2789:1993.
28. Pearson JD, Morrell CH, Landis PK, Carter HB, Brant LJ: Mixed-effects regression models for studying the natural history of prostate disease. Stat Med 13:587-601, 1994.
29. Krahn MD, Mahoney JE, Eckman MH, Trachtenburg J, Pauker Sg, Detsky AS: Screening for prostate cancer: A decision-analytic view. JAMA 272:773-780, 1994.